Erythropoietin in neonatal brain protection: the past, the present and the future

Brain Dev. 2011 Sep;33(8):632-43. doi: 10.1016/j.braindev.2010.10.014. Epub 2010 Nov 24.

Abstract

Over the last decade, neuroprotective effects of erythropoietin (Epo) and its underlying mechanisms in terms of signal transduction pathways have been defined and there is a growing interest in the potential therapeutic use of Epo for neuroprotection. Several mechanisms by which Epo provides neuroprotection are recognized. In this review, we focused on the neuroprotective mechanisms of Epo and provide a short overview on both experimental and clinical studies, testing Epo as a neuroprotective agent in the neonatal brain injury, and the safety concerns with the clinical use of Epo treatment in neonates.

Publication types

  • Review

MeSH terms

  • Blood-Brain Barrier / metabolism
  • Brain Injuries / drug therapy
  • Brain Injuries / metabolism
  • Brain Injuries / physiopathology*
  • Clinical Trials as Topic
  • Erythropoietin / metabolism*
  • Erythropoietin / therapeutic use
  • Humans
  • Infant, Newborn
  • Neuroglia / metabolism
  • Neurons / metabolism
  • Neuroprotective Agents / metabolism*
  • Signal Transduction / physiology

Substances

  • Neuroprotective Agents
  • Erythropoietin